Antibodies News and Research

RSS

New antibody appears to block sensations of pain, itching in mouse model

Duke University researchers have found an antibody that simultaneously blocks the sensations of pain and itching in studies with mice.

23 May 2014

Novel scrapbook-inspired test helps patients diagnosed with hepatitis C

To the relief of patients diagnosed with hepatitis C, the U.S. Food and Drug Administration approved two new treatments late last year, and a few more are on the way.

22 May 2014

Cell Science Systems launches new blood test profile for GI disorders

Distinguishing the cause of gut disorders can be complicated. Therefore, Cell Science Systems, Corp. today announced the launch of a new test to help clinicians reach a diagnosis; and, suggest dietary strategies to improve whatever gut malady a person may have.

21 May 2014

New antibody can improve quality of life for individuals with asthma

Researchers at St. Joseph's Healthcare Hamilton and McMaster University have successfully tested an antibody that can improve the quality of life for individuals with asthma by relieving inflammation in the lungs.

21 May 2014

Sanofi presents Phase II trial results for investigational vaccine for prevention of CDI

Sanofi Pasteur, the vaccines division of Sanofi, presented Phase II (H-030-012) trial results for an investigational vaccine for the prevention of Clostridium difficile infection at the 114th General Meeting of the American Society for Microbiology.

20 May 2014

Three scientists selected to receive NIDA's 2014 Avant-Garde Award for HIV/AIDS Research

With proposals ranging from enhancing the immune system's ability to fight HIV infection to improving long-term immune health in HIV-infected drug users, three scientists have been chosen to receive the 2014 Avant-Garde Award for HIV/AIDS Research from the National Institute on Drug Abuse, part of the National Institutes of Health.

19 May 2014

IAVI: Together, we can achieve a world without AIDS

Do you remember the world before HIV/AIDS? Where will you be when the shadow of this disease is finally gone?

19 May 2014

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb Company today announced results from a Phase 2 and a Phase 1b study of its investigational PD-1 immune checkpoint inhibitor nivolumab in patients with advanced or metastatic renal cell carcinoma (RCC), commonly known as kidney cancer.

16 May 2014

Kymab raises US$40 million in Series B financing

Kymab, a monoclonal antibody biopharmaceutical company, announced today it has successfully raised US$40 million in a Series B financing.

16 May 2014

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Bristol-Myers Squibb Company today announced updated survival data from the advanced melanoma cohort of Phase 1b study.

16 May 2014

Scientists reveal how and why immune system's B cells respond only to true threats

The immune system's B cells protect us from disease by producing antibodies, or "smart bullets," that specifically target invaders such as pathogens and viruses while leaving harmless molecules alone.

16 May 2014

Study led by TSRI scientists likely to influence future designs for HIV vaccines, antibody-based therapies

A vaccine or other therapy directed at a single site on a surface protein of HIV could in principle neutralize nearly all strains of the virus—thanks to the diversity of targets the site presents to the human immune system.

16 May 2014

Shark antibodies reveal evolutionary principles of immunoglobulins

Custom-tailored antibodies are regarded as promising weapons against a multitude of serious illnesses. Since they can accurately recognize specific structures on the surface of viruses, bacteria or cancer cells, they are already being deployed successfully in cancer diagnostics and therapy, as well as against numerous other diseases. The stability of the sensitive antibodies is a decisive factor in every step, from production and storage to therapeutic application.

15 May 2014

Sorrento Therapeutics prices underwritten public offering of 4,765,000 shares of common stock

Sorrento Therapeutics, Inc. ("Sorrento" or the "Company"), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced the pricing of an underwritten public offering of 4,765,000 shares of common stock at a public offering price of $5.25 per share.

15 May 2014

Scripps Research Institute scientists show AIDS vaccine could work against changeable site on HIV

A vaccine or other therapy directed at a single site on a surface protein of HIV could in principle neutralize nearly all strains of the virus-thanks to the diversity of targets the site presents to the human immune system.

15 May 2014

Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Epilepsy is a group of neurological disorders often characterized by seizures and cognitive impairment due to electrical disturbances in the brain.

From Quest Diagnostics 14 May 2014

New breakthrough offers easier way of detecting pathogenic bacteria outside clinical setting

The breakthrough, published in the journal Nature Materials, could offer an easier way of detecting pathogenic bacteria outside of a clinical setting and could be particularly important for the developing world, where access to more sophisticated laboratory techniques is often limited.

13 May 2014

Carbohydrate-binding proteins fill in gaps in immune defenses

Our bodies produce a family of proteins that recognize and kill bacteria whose carbohydrate coatings resemble those of our own cells too closely, scientists have discovered.

13 May 2014

FDA approves Bayer's Kogenate FS antihemophilic factor VIII to prevent bleeding episodes in adults with hemophilia A

Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication for Bayer's Kogenate® FS antihemophilic factor VIII (recombinant), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A.

12 May 2014

Pfizer reports positive results from rLP2086 Phase 2 study for invasive meningococcal disease

Pfizer Inc. announced today the results from two Phase 2 studies of bivalent rLP2086, Pfizer's recombinant vaccine candidate, currently under development for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 to 25 year olds.

12 May 2014

Antibodies News and Research

New antibody appears to block sensations of pain, itching in mouse model

Novel scrapbook-inspired test helps patients diagnosed with hepatitis C

Cell Science Systems launches new blood test profile for GI disorders

New antibody can improve quality of life for individuals with asthma

Sanofi presents Phase II trial results for investigational vaccine for prevention of CDI

Three scientists selected to receive NIDA's 2014 Avant-Garde Award for HIV/AIDS Research

IAVI: Together, we can achieve a world without AIDS

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Kymab raises US$40 million in Series B financing

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Scientists reveal how and why immune system's B cells respond only to true threats

Study led by TSRI scientists likely to influence future designs for HIV vaccines, antibody-based therapies

Shark antibodies reveal evolutionary principles of immunoglobulins

Sorrento Therapeutics prices underwritten public offering of 4,765,000 shares of common stock

Scripps Research Institute scientists show AIDS vaccine could work against changeable site on HIV

Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

New breakthrough offers easier way of detecting pathogenic bacteria outside clinical setting

Carbohydrate-binding proteins fill in gaps in immune defenses

FDA approves Bayer's Kogenate FS antihemophilic factor VIII to prevent bleeding episodes in adults with hemophilia A

Pfizer reports positive results from rLP2086 Phase 2 study for invasive meningococcal disease

From IHC to multiplexing: A practical guide for modern tissue analysis eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo